Chemotherapy-Induced Nausea and Vomiting
Conditions
Interventions
Group 1 (single dose of NEPA + olanzapine + dexamethasone):NA
Group 2 (fosaprepitant 150mg + palonosetron 0.75mg + olanzapine + dexamethasone):NA
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. A patient diagnosed with stage III-IVa locally advanced nasopharyngeal carcinoma (AJCC 8th edition) through pathological examination completed all cisplatin based IC and CCRT treatments at our hospital. 2. Age: 18-75 years old, ECOG score status score 0-2. KPS score >= 80 points. 3. BMI ranges from 18.5 to 23.9kg/? 4. Heart function, kidney function, liver function, and bone marrow function are fully maintained. 5. There were no symptoms of nausea or vomiting 24 hours before the start of chemotherapy. 6. Within 30 days prior to chemotherapy, no phenothiazine drugs or unplanned use of phenothiazine drugs as antipsychotic drugs were used during the study period (patients may receive emergency antiemetic treatment with prochlorperazine and other phenothiazine drugs). 7. There is no known allergy to NEPA. 8. Ability to read, understand, and complete Chinese research diaries and surveys.
Exclusion criteria
Exclusion criteria: 1. Before starting chemotherapy, certain diseases have been shown to have potential risks of nausea and vomiting, such as severe cognitive impairment, history of symptomatic central nervous system disorders, chronic alcoholism, active peptic ulcers, gastrointestinal obstruction, hypercalcemia, etc. 2. Known heart diseases within the past 6 months, such as arrhythmia, uncontrolled congestive heart failure, or acute myocardial infarction. 3. Within 24 hours prior to the start of chemotherapy, the patient received any potential emetic or antiemetic medication. 4. The patient receives potent or moderate CYP3A4 inhibitor treatment within one week and any CYP3A4 inducer treatment within 1-5 days before or after treatment. 5. Patients who experience vomiting or nausea one week before chemotherapy have undergone surgery or abdominal radiation therapy (subphrenic) or pelvic area, and received antiemetic medication within two days before chemotherapy. 6. Data loss and incomplete clinical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relief rate of nausea and vomiting after chemotherapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time and severity of nausea and vomiting after chemotherapy; | — |
Countries
China
Contacts
Public ContactLuo Haiqing
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed